Go to
current issue
-
FDA approves first HER2 × HER3 bispecific antibody Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-12-18
Discover the world’s best science and medicine | Nature.com
-
Pairing up with GLP-1 to combat obesity Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-12-18
Discover the world’s best science and medicine | Nature.com
-
Open Targets: 10 years of partnership in target discovery Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-12-17 David G. Hulcoop, Gosia Trynka, Ellen M. McDonagh
The Open Targets consortium was founded in 2014 to translate insights from genetics and functional genomics into identifying and prioritizing therapeutic targets. We highlight key achievements and insights stemming from this partnership of academic and industry scientists.
-
Chemical engineering of CRISPR–Cas systems for therapeutic application Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-12-17 Halle M. Barber, Adrian A. Pater, Keith T. Gagnon, Masad J. Damha, Daniel O’Reilly
-
Harnessing the biology of regulatory T cells to treat disease Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-12-16 Christine M. Wardell, Dominic A. Boardman, Megan K. Levings
-
IRDiRC perspectives on the application of digital biomarkers in therapeutic development for rare diseases Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-12-16 Rajesh Krishna, Anneliene H. Jonker, Thomas Morel, Ken Sakushima, Anna M. G. Pasmooij, Daniel O’Connor
New approaches are needed to streamline clinical trials of drugs for patients with rare diseases. Digital biomarkers offer one such approach, but several challenges must be addressed to realize their potential.
-
Targeting metabolic dysfunction of CD8 T cells and natural killer cells in cancer Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-12-12 Sébastien Viel, Eric Vivier, Thierry Walzer, Antoine Marçais
-
NaV1.8 inhibitor poised to provide opioid-free pain relief Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-12-12
Vertex’s first-in-class suzetrigine could soon usher in a new class of analgesic.
-
Upcoming FDA approval decisions in Q1 2025 Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-12-11
Discover the world’s best science and medicine | Nature.com
-
Top product forecasts for 2025 Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-12-10
Discover the world’s best science and medicine | Nature.com
-
Can non-canonical amino acids open up non-canonical drug discovery opportunities? Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-12-09
Jason Chin, head of Cambridge’s Centre for Chemical & Synthetic Biology and CSO of Constructive Bio, discusses the role for unnatural amino acids in biologic therapies.
-
Showing tau the exit Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-12-05
Discover the world’s best science and medicine | Nature.com
-
FDA approves first menin inhibitor, for acute leukaemia Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-12-03
Discover the world’s best science and medicine | Nature.com
-
Covalent inhibitor engages oncogenic AKT kinase Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-12-03
Discover the world’s best science and medicine | Nature.com
-
Vaccines for cancer prevention: exploring opportunities and navigating challenges Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-12-02 Michele Graciotti, Lana E. Kandalaft
-
Antiviral target compound profile for pandemic preparedness Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-12-02 James F. Demarest, Ruxandra Draghia-Akli, Tomas Cihlar, Kenneth Bradley, John A. T. Young, Richa Chandra, Sujata Vaidyanathan, Margaret Chu-Moyer, Christopher L. Lynch, Andrew Campbell, Kumar Singh Saikatendu, John P. Bilello, Yoshihiko Murata, Marnix van Loock, Aeron C. Hurt, Timothy Tellinghuisen, Lee Ruggiero, Richard Mackman, Nina M. Hill, John C. Pottage
The recent experiences with the pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have demonstrated the urgent need for a structured approach towards accelerated and more effective discovery, development and delivery of vaccines, therapeutics, and diagnostics to minimize the overall impact of the next pandemic (see Related links). This urgency is further highlighted
-
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH) Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-11-28 Albert Do, Frhaan Zahrawi, Wajahat Z. Mehal
-
Understanding cholestatic itch Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-11-27
Discover the world’s best science and medicine | Nature.com
-
The targeted protein degradation landscape Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-11-27
Discover the world’s best science and medicine | Nature.com
-
Author Correction: Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-11-27 Lieselotte Vande Walle, Mohamed Lamkanfi
-
Expanding the ligandable proteome Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-11-27
Discover the world’s best science and medicine | Nature.com
-
ENGases to treat IgG-mediated diseases Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-11-27
Discover the world’s best science and medicine | Nature.com
-
Multi-TACs target solid tumours Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-11-27
Discover the world’s best science and medicine | Nature.com
-
FDA approves first biparatopic antibody therapy Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-11-26
Discover the world’s best science and medicine | Nature.com
-
Author Correction: B cell depletion therapies in autoimmune disease: advances and mechanistic insights Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-11-26 Dennis S. W. Lee, Olga L. Rojas, Jennifer L. Gommerman
Correction to: Nature Reviews Drug Discovery https://doi.org/10.1038/s41573-020-00092-2, published online 15 December 2020.
-
FDA approves second TTR stabilizer for cardiac amyloidosis Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-11-25
Discover the world’s best science and medicine | Nature.com
-
StitchR platform joins up gene therapy payloads Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-11-22
Discover the world’s best science and medicine | Nature.com
-
Targeting lysine acetylation readers and writers Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-11-21 Ming-Ming Zhou, Philip A. Cole
-
NK2R agonist delivers one-two punch to obesity Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-11-21
Discover the world’s best science and medicine | Nature.com
-
FDA approves l-amino acid decarboxylase deficiency gene therapy Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-11-15
Discover the world’s best science and medicine | Nature.com
-
Senescence as a therapeutic target in cancer and age-related diseases Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-11-15 Domhnall McHugh, Imanol Durán, Jesús Gil
-
DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-11-12 Yvette Drew, Frank T Zenke, Nicola J Curtin
-
Benchmarking recruitment rates for phase III trials Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-11-08
Discover the world’s best science and medicine | Nature.com
-
Antimalarial drug hits cardiac fibrosis Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-11-05
Discover the world’s best science and medicine | Nature.com
-
Lundbeck pays US$2.6 billion for Longboard and its lead epilepsy drug Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-11-05
Discover the world’s best science and medicine | Nature.com
-
JAK inhibition combats adverse skin reaction Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-11-05
Discover the world’s best science and medicine | Nature.com
-
The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-11-04 Anneliene H. Jonker, Elena-Alexandra Tataru, Holm Graessner, David Dimmock, Adam Jaffe, Gareth Baynam, James Davies, Shruti Mitkus, Oxana Iliach, Rich Horgan, Erika F. Augustine, Alison Bateman-House, Anna Maria Gerdina Pasmooij, Tim Yu, Matthis Synofzik, Julie Douville, Larissa Lapteva, Philip John Brooks, Daniel O’Connor, Annemieke Aartsma-Rus
-
Anti-tau antibody stumbles in phase II Alzheimer trial Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-11-01
Discover the world’s best science and medicine | Nature.com
-
Bivalent molecules unmute silenced genes Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-11-01
Discover the world’s best science and medicine | Nature.com
-
How GLP-1 went from being a hard-to-handle hormone to a blockbuster success Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-11-01
Lotte Bjerre Knudsen, chief scientific advisor in research and early development at Novo Nordisk, discusses the past and future of GLP-1s and related anti-obesity drugs.
-
FDA approves first anti-TFPI antibody for haemophilia A and B Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-30
Discover the world’s best science and medicine | Nature.com
-
FDA approves PI3Kα inhibitor that does double duty as a degrader Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-30
Discover the world’s best science and medicine | Nature.com
-
Multivalent vaccine tackles C. difficile Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-30
Discover the world’s best science and medicine | Nature.com
-
Antibody vanquishes SARS-CoV-2 variants Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-29
Discover the world’s best science and medicine | Nature.com
-
Glucose-sensitive insulin protects against hypoglycaemia Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-28
Discover the world’s best science and medicine | Nature.com
-
Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-24 Michael Croft, Shahram Salek-Ardakani, Carl F. Ware
-
FDA approves first claudin-18.2-targeted antibody for gastric cancer Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-22
Discover the world’s best science and medicine | Nature.com
-
Advanced technologies for the development of infectious disease vaccines Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-21 Akash Gupta, Arnab Rudra, Kaelan Reed, Robert Langer, Daniel G. Anderson
-
Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-18 Paul J. Carter, Valerie Quarmby
-
TLK2: a target for cancer and viral latency Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-17
Discover the world’s best science and medicine | Nature.com
-
New eyes on the infectious disease prize Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-15
Jeanne Marrazzo, the director of the NIAID, discusses post-COVID pandemic preparedness, H5N1 avian flu and the tension between infectious disease protection versus profit.
-
Protein degraders push into novel target space Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-14
Clinic-ready molecular glues and heterobifunctional PROTAC drugs are taking targeted protein degradation into uncharted territory.
-
Reply to ‘Bayesian approaches in drug development: continuing the virtuous cycle’ Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-10 Stephen J. Ruberg
We are thankful that Igl and Constant1 are joining the creation of the virtuous cycle for the use of Bayesian approaches in clinical trials. Their comments help to expand the considerations from the original paper2 and bring additional perspectives to bear on Bayesian approaches. We are in general agreement with their Correspondence. We will make a few additional comments on topics in the order they
-
Bayesian approaches in drug development: continuing the virtuous cycle Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-10 Wilmar Igl, John Constant
Ruberg et al. recently published an article with the aim of starting a virtuous cycle in the use of Bayesian approaches in drug development (Nat. Rev. Drug Discov. 22, 235–250; 2023)1. Here, we would like to extend important arguments of their article and add recommendations for using Bayesian statistics2.
-
FDA new drug approvals in Q3 2024 Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-10
Discover the world’s best science and medicine | Nature.com
-
Tumour cells get a dendritic cell makeover Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-08
Discover the world’s best science and medicine | Nature.com
-
mRNA vaccines for infectious diseases — advances, challenges and opportunities Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-04 Norbert Pardi, Florian Krammer
-
A viral–lipid hybrid delivery system for genetic therapies Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-03
Discover the world’s best science and medicine | Nature.com
-
Two decades of new drug approvals in Japan Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-02
Discover the world’s best science and medicine | Nature.com
-
FDA approves first monoclonal antibody for COPD Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-01
Discover the world’s best science and medicine | Nature.com
更新日期：2024-12-02
Copyright © 2014-2024 北京衮雪科技有限公司 All Rights Reserved
京ICP备11026495号-2
京公网安备 11010802027423号
京公网安备 11010802027423号